Last reviewed · How we verify
Tetracycline,Metronidazole
This combination of tetracycline (a protein synthesis inhibitor) and metronidazole (a nucleic acid damaging agent) works synergistically to kill bacteria and anaerobic microorganisms through dual antimicrobial pathways.
This combination of tetracycline (a protein synthesis inhibitor) and metronidazole (a nucleic acid damaging agent) works synergistically to kill bacteria and anaerobic microorganisms through dual antimicrobial pathways. Used for Polymicrobial infections including anaerobic bacteria, Periodontal disease and oral infections, Intra-abdominal infections.
At a glance
| Generic name | Tetracycline,Metronidazole |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Antibiotic combination |
| Target | Bacterial 30S ribosome (tetracycline); anaerobic DNA/RNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation. Metronidazole is a prodrug that generates reactive oxygen species and damages DNA/RNA in anaerobic organisms. Together, they provide broad-spectrum coverage against aerobic and anaerobic bacteria, commonly used in polymicrobial infections.
Approved indications
- Polymicrobial infections including anaerobic bacteria
- Periodontal disease and oral infections
- Intra-abdominal infections
- Mixed aerobic-anaerobic infections
Common side effects
- Gastrointestinal upset (nausea, diarrhea)
- Photosensitivity (tetracycline)
- Metallic taste (metronidazole)
- Vaginal candidiasis
- Headache
- Peripheral neuropathy (metronidazole, rare)
Key clinical trials
- Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (PHASE4)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: